Glenmark Specialty SA Secures FDA Approval for Fluticasone Propionate Inhalation Aerosol with Exclusivity Glenmark Specialty SA has received FDA approval for its Fluticasone Propionate Inhalation Aerosol, marking a significant milestone with 180 days of generic therapy exclusivity.

Glenmark Specialty SA Secures FDA Approval for Fluticasone Propionate Inhalation Aerosol with Exclusivity #United_States #FDA_Approval #Glenmark_Pharmaceuticals #Fluticasone_Propionate #Elmwood_Park,_NJ